IGFBP2 in cancer: Pathological role and clinical significance (Review)
- Authors:
- Lai‑Feng Wei
- Xue‑Fen Weng
- Xu‑Chun Huang
- Yu‑Hui Peng
- Hai‑Peng Guo
- Yi‑Wei Xu
-
Affiliations: Department of Clinical Laboratory Medicine, The Cancer Hospital of Shantou University Medical College, Shantou 515041, P.R. China, Department of Head and Neck Surgery, The Cancer Hospital of Shantou University Medical College, Shantou 515041, P.R. China - Published online on: December 9, 2020 https://doi.org/10.3892/or.2020.7892
- Pages: 427-438
This article is mentioned in:
Abstract
 |
|
Baxter RC: Insulin-like growth factor (IGF)-binding proteins: Interactions with IGFs and intrinsic bioactivities. Am J Physiol Endocrinol Metab. 278:E967–E976. 2000. View Article : Google Scholar : PubMed/NCBI | |
|
Rajaram S, Baylink DJ and Mohan S: Insulin-like growth factor-binding proteins in serum and other biological fluids: Regulation and functions. Endocr Rev. 18:801–831. 1997. View Article : Google Scholar : PubMed/NCBI | |
|
Bach LA: IGF-binding proteins. J Mol Endocrinol. 61:T11–T28. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Baxter RC: IGF binding proteins in cancer: Mechanistic and clinical insights. Nat Rev Cancer. 14:329–341. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Yu H and Rohan T: Role of the insulin-like growth factor family in cancer development and progression. J Natl Cancer Inst. 92:1472–1489. 2000. View Article : Google Scholar : PubMed/NCBI | |
|
Russo VC, Azar WJ, Yau SW, Sabin MA and Werther GA: IGFBP-2: The dark horse in metabolism and cancer. Cytokine Growth Factor Rev. 26:329–346. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Zeng L, Perks CM and Holly JM: IGFBP-2/PTEN: A critical interaction for tumours and for general physiology? Growth Horm IGF Res. 25:103–107. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Chua CY, Liu Y, Granberg KJ, Hu L, Haapasalo H, Annala MJ, Cogdell DE, Verploegen M, Moore LM, Fuller GN, et al: IGFBP2 potentiates nuclear EGFR-STAT3 signaling. Oncogene. 35:738–747. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Gao S, Sun Y, Zhang X, Hu L, Liu Y, Chua CY, Phillips LM, Ren H, Fleming JB, Wang H, et al: IGFBP2 activates the NF-κB pathway to Drive epithelial-mesenchymal transition and invasive character in pancreatic ductal adenocarcinoma. Cancer Res. 76:6543–6554. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Fuller GN, Rhee CH, Hess KR, Caskey LS, Wang R, Bruner JM, Yung WK and Zhang W: Reactivation of insulin-like growth factor binding protein 2 expression in glioblastoma multiforme: A revelation by parallel gene expression profiling. Cancer Res. 59:4228–4232. 1999.PubMed/NCBI | |
|
McDonald KL, O'Sullivan MG, Parkinson JF, Shaw JM, Payne CA, Brewer JM, Young L, Reader DJ, Wheeler HT, Cook RJ, et al: IQGAP1 and IGFBP2: Valuable biomarkers for determining prognosis in glioma patients. J Neuropathol Exp Neurol. 66:405–417. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Lin Y, Jiang T, Zhou K, Xu L, Chen B, Li G, Qiu X, Jiang T, Zhang W and Song SW: Plasma IGFBP-2 levels predict clinical outcomes of patients with high-grade gliomas. Neuro Oncol. 11:468–476. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Dunlap SM, Celestino J, Wang H, Jiang R, Holland EC, Fuller GN and Zhang W: Insulin-like growth factor binding protein 2 promotes glioma development and progression. Proc Natl Acad Sci USA. 104:11736–11741. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Wang H, Wang H, Shen W, Huang H, Hu L, Ramdas L, Zhou YH, Liao WS, Fuller GN and Zhang W: Insulin-like growth factor binding protein 2 enhances glioblastoma invasion by activating invasion-enhancing genes. Cancer Res. 63:4315–4321. 2003.PubMed/NCBI | |
|
Phillips LM, Zhou X, Cogdell DE, Chua CY, Huisinga A, R Hess K, Fuller GN and Zhang W: Glioma progression is mediated by an addiction to aberrant IGFBP2 expression and can be blocked using anti-IGFBP2 strategies. J Pathol. 239:355–364. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Flyvbjerg A, Mogensen O, Mogensen B and Nielsen OS: Elevated serum insulin-like growth factor-binding protein 2 (IGFBP-2) and decreased IGFBP-3 in epithelial ovarian cancer: Correlation with cancer antigen 125 and tumor-associated trypsin inhibitor. J Clin Endocrinol Metab. 82:2308–2313. 1997. View Article : Google Scholar : PubMed/NCBI | |
|
Lee EJ, Mircean C, Shmulevich I, Wang H, Liu J, Niemistö A, Kavanagh JJ, Lee JH and Zhang W: Insulin-like growth factor binding protein 2 promotes ovarian cancer cell invasion. Mol Cancer. 4:72005. View Article : Google Scholar : PubMed/NCBI | |
|
Wang H, Rosen DG, Wang H, Fuller GN, Zhang W and Liu J: Insulin-like growth factor-binding protein 2 and 5 are differentially regulated in ovarian cancer of different histologic types. Mod Pathol. 19:1149–1156. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Kanety H, Kattan M, Goldberg I, Kopolovic J, Ravia J, Menczer J and Karasik A: Increased insulin-like growth factor binding protein-2 (IGFBP-2) gene expression and protein production lead to high IGFBP-2 content in malignant ovarian cyst fluid. Br J Cancer. 73:1069–1073. 1996. View Article : Google Scholar : PubMed/NCBI | |
|
Baron-Hay S, Boyle F, Ferrier A and Scott C: Elevated serum insulin-like growth factor binding protein-2 as a prognostic marker in patients with ovarian cancer. Clin Cancer Res. 10:1796–1806. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Russell MR, Graham C, D'Amato A, Gentry-Maharaj A, Ryan A, Kalsi JK, Ainley C, Whetton AD, Menon U, Jacobs I and Graham RLJ: A combined biomarker panel shows improved sensitivity for the early detection of ovarian cancer allowing the identification of the most aggressive type II tumours. Br J Cancer. 117:666–674. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Biernacka KM, Uzoh CC, Zeng L, Persad RA, Bahl A, Gillatt D, Perks CM and Holly JM: Hyperglycaemia-induced chemoresistance of prostate cancer cells due to IGFBP2. Endocr Relat Cancer. 20:741–751. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Kanety H, Madjar Y, Dagan Y, Levi J, Papa MZ, Pariente C, Goldwasser B and Karasik A: Serum insulin-like growth factor-binding protein-2 (IGFBP-2) is increased and IGFBP-3 is decreased in patients with prostate cancer: Correlation with serum prostate-specific antigen. J Clin Endocrinol Metab. 77:229–233. 1993. View Article : Google Scholar : PubMed/NCBI | |
|
Cohen P, Peehl DM, Stamey TA, Wilson KF, Clemmons DR and Rosenfeld RG: Elevated levels of insulin-like growth factor-binding protein-2 in the serum of prostate cancer patients. J Clin Endocrinol Metab. 76:1031–1035. 1993. View Article : Google Scholar : PubMed/NCBI | |
|
Shariat SF, Lamb DJ, Kattan MW, Nguyen C, Kim J, Beck J, Wheeler TM and Slawin KM: Association of preoperative plasma levels of insulin-like growth factor I and insulin-like growth factor binding proteins-2 and −3 with prostate cancer invasion, progression, and metastasis. J Clin Oncol. 20:833–841. 2002. View Article : Google Scholar : PubMed/NCBI | |
|
Kendrick ZW, Firpo MA, Repko RC, Scaife CL, Adler DG, Boucher KM and Mulvihill SJ: Serum IGFBP2 and MSLN as diagnostic and prognostic biomarkers for pancreatic cancer. HPB (Oxford). 16:670–676. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Yoneyama T, Ohtsuki S, Honda K, Kobayashi M, Iwasaki M, Uchida Y, Okusaka T, Nakamori S, Shimahara M, Ueno T, et al: Identification of IGFBP2 and IGFBP3 as compensatory biomarkers for CA19-9 in early-stage pancreatic cancer using a combination of antibody-based and LC-MS/MS-based proteomics. PLoS One. 11:e01610092016. View Article : Google Scholar : PubMed/NCBI | |
|
Busund LT, Richardsen E, Busund R, Ukkonen T, Bjørnsen T, Busch C and Stalsberg H: Significant expression of IGFBP2 in breast cancer compared with benign lesions. J Clin Pathol. 58:361–366. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Dean SJ, Perks CM, Holly JM, Bhoo-Pathy N, Looi LM, Mohammed NA, Mun KS, Teo SH, Koobotse MO, Yip CH and Rhodes A: Loss of PTEN expression is associated with IGFBP2 expression, younger age, and late stage in triple-negative breast cancer. Am J Clin Pathol. 141:323–333. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Garner CP, Ding YC, John EM, Ingles SA, Olopade OI, Huo D, Adebamowo C, Ogundiran T and Neuhausen SL: Genetic variation in IGFBP2 and IGFBP5 is associated with breast cancer in populations of African descent. Hum Genet. 123:247–255. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Wang H, Arun BK, Wang H, Fuller GN, Zhang W, Middleton LP and Sahin AA: IGFBP2 and IGFBP5 overexpression correlates with the lymph node metastasis in T1 breast carcinomas. Breast J. 14:261–267. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Migita T, Narita T, Asaka R, Miyagi E, Nagano H, Nomura K, Matsuura M, Satoh Y, Okumura S, Nakagawa K, et al: Role of insulin-like growth factor binding protein 2 in lung adenocarcinoma: IGF-independent antiapoptotic effect via caspase-3. Am J Pathol. 176:1756–1766. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Guo C, Lu H, Gao W, Wang L, Lu K, Wu S, Pataer A, Huang M, El-Zein R, Lin T, et al: Insulin-like growth factor binding protein-2 level is increased in blood of lung cancer patients and associated with poor survival. PLoS One. 8:e749732013. View Article : Google Scholar : PubMed/NCBI | |
|
Ladd JJ, Busald T, Johnson MM, Zhang Q, Pitteri SJ, Wang H, Brenner DE, Lampe PD, Kucherlapati R, Feng Z, et al: Increased plasma levels of the APC-interacting protein MAPRE1, LRG1, and IGFBP2 preceding a diagnosis of colorectal cancer in women. Cancer Prev Res (Phila). 5:655–664. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Liou JM, Shun CT, Liang JT, Chiu HM, Chen MJ, Chen CC, Wang HP, Wu MS and Lin JT: Plasma insulin-like growth factor-binding protein-2 levels as diagnostic and prognostic biomarker of colorectal cancer. J Clin Endocrinol Metab. 95:1717–1725. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Renehan AG, Jones J, Potten CS, Shalet SM and O'Dwyer ST: Elevated serum insulin-like growth factor (IGF)-II and IGF binding protein-2 in patients with colorectal cancer. Br J Cancer. 83:1344–1350. 2000. View Article : Google Scholar : PubMed/NCBI | |
|
Wang H, Shen SS, Wang H, Diwan AH, Zhang W, Fuller GN and Prieto VG: Expression of insulin-like growth factor-binding protein 2 in melanocytic lesions. J Cutan Pathol. 30:599–605. 2003. View Article : Google Scholar : PubMed/NCBI | |
|
Ranke MB, Maier KP, Schweizer R, Stadler B, Schleicher S, Elmlinger MW and Flehmig B: Pilot study of elevated levels of insulin-like growth factor-binding protein-2 as indicators of hepatocellular carcinoma. Horm Res. 60:174–180. 2003.PubMed/NCBI | |
|
Zhou Q, Mao YQ, Jiang WD, Chen YR, Huang RY, Zhou XB, Wang YF, Shi Z, Wang ZS and Huang RP: Development of IGF signaling antibody arrays for the identification of hepatocellular carcinoma biomarkers. PLoS One. 7:e468512012. View Article : Google Scholar : PubMed/NCBI | |
|
Guo Q, Yu DY, Yang ZF, Liu DY, Cao HQ and Liao XW: IGFBP2 upregulates ZEB1 expression and promotes hepatocellular carcinoma progression through NF-κB signaling pathway. Dig Liver Dis. 52:573–581. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Shi LH, Zhu XQ, Zhao GH, Xia YB and Zhang YS: Expression of insulin-like growth factor binding protein-2 in gastric carcinoma and its relationship with cell proliferation. World J Gastroenterol. 12:6285–6289. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Zhang L, Huang W, Chen J, Zhou X, Lu Z and Zhou H: Expression of IGFBP2 in gastric carcinoma and relationship with clinicopathologic parameters and cell proliferation. Dig Dis Sci. 52:248–253. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Tombolan L, Orso F, Guzzardo V, Casara S, Zin A, Bonora M, Romualdi C, Giorgi C, Bisogno G, Alaggio R, et al: High IGFBP2 expression correlates with tumor severity in pediatric rhabdomyosarcoma. Am J Pathol. 179:2611–2624. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Vorwerk P, Mohnike K, Wex H, Röhl FW, Zimmermann M, Blum WF and Mittler U: Insulin-like growth factor binding protein-2 at diagnosis of childhood acute lymphoblastic leukemia and the prediction of relapse risk. J Clin Endocrinol Metab. 90:3022–3027. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Dawczynski K, Kauf E, Schlenvoigt D, Gruhn B, Fuchs D and Zintl F: Elevated serum insulin-like growth factor binding protein-2 is associated with a high relapse risk after hematopoietic stem cell transplantation in childhood AML. Bone Marrow Transplant. 37:589–594. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Yao X, Sun S, Zhou X, Guo W and Zhang L: IGF-binding protein 2 is a candidate target of therapeutic potential in cancer. Tumour Biol. 37:1451–1459. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Holmes KM, Annala M, Chua CY, Dunlap SM, Liu Y, Hugen N, Moore LM, Cogdell D, Hu L, Nykter M, et al: Insulin-like growth factor-binding protein 2-driven glioma progression is prevented by blocking a clinically significant integrin, integrin-linked kinase, and NF-κB network. Proc Natl Acad Sci USA. 109:3475–3480. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Liu Y, Li F, Yang YT, Xu XD, Chen JS, Chen TL, Chen HJ, Zhu YB, Lin JY, Li Y, et al: IGFBP2 promotes vasculogenic mimicry formation via regulating CD144 and MMP2 expression in glioma. Oncogene. 38:1815–1831. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Lin KW, Liao A and Qutub AA: Simulation predicts IGFBP2-HIF1α interaction drives glioblastoma growth. PLoS Comput Biol. 11:e10041692015. View Article : Google Scholar : PubMed/NCBI | |
|
Mehrian-Shai R, Chen CD, Shi T, Horvath S, Nelson SF, Reichardt JK and Sawyers CL: Insulin growth factor-binding protein 2 is a candidate biomarker for PTEN status and PI3K/Akt pathway activation in glioblastoma and prostate cancer. Proc Natl Acad Sci USA. 104:5563–5568. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Patil SS, Gokulnath P, Bashir M, Shwetha SD, Jaiswal J, Shastry AH, Arimappamagan A, Santosh V and Kondaiah P: Insulin-like growth factor binding protein-2 regulates β-catenin signaling pathway in glioma cells and contributes to poor patient prognosis. Neuro Oncol. 18:1487–1497. 2016.PubMed/NCBI | |
|
Han S, Li Z, Master LM, Master ZW and Wu A: Exogenous IGFBP-2 promotes proliferation, invasion, and chemoresistance to temozolomide in glioma cells via the integrin β1-ERK pathway. Br J Cancer. 111:1400–1409. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Moore MG, Wetterau LA, Francis MJ, Peehl DM and Cohen P: Novel stimulatory role for insulin-like growth factor binding protein-2 in prostate cancer cells. Int J Cancer. 105:14–19. 2003. View Article : Google Scholar : PubMed/NCBI | |
|
Uzoh CC, Holly JM, Biernacka KM, Persad RA, Bahl A, Gillatt D and Perks CM: Insulin-like growth factor-binding protein-2 promotes prostate cancer cell growth via IGF-dependent or -independent mechanisms and reduces the efficacy of docetaxel. Br J Cancer. 104:1587–1593. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Sehgal P, Kumar N, Praveen Kumar VR, Patil S, Bhattacharya A, Vijaya Kumar M, Mukherjee G and Kondaiah P: Regulation of protumorigenic pathways by insulin like growth factor binding protein2 and its association along with β-catenin in breast cancer lymph node metastasis. Mol Cancer. 12:632013. View Article : Google Scholar : PubMed/NCBI | |
|
Perks CM, Vernon EG, Rosendahl AH, Tonge D and Holly JM: IGF-II and IGFBP-2 differentially regulate PTEN in human breast cancer cells. Oncogene. 26:5966–5972. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Chakrabarty S and Kondratick L: Insulin-like growth factor binding protein-2 stimulates proliferation and activates multiple cascades of the mitogen-activated protein kinase pathways in NIH-OVCAR3 human epithelial ovarian cancer cells. Cancer Biol Ther. 5:189–197. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Lu H, Wang L, Gao W, Meng J, Dai B, Wu S, Minna J, Roth JA, Hofstetter WL, Swisher SG and Fang B: IGFBP2/FAK pathway is causally associated with dasatinib resistance in non-small cell lung cancer cells. Mol Cancer Ther. 12:2864–2873. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Ben-Shmuel A, Shvab A, Gavert N, Brabletz T and Ben-Ze'ev A: Global analysis of L1-transcriptomes identified IGFBP-2 as a target of ezrin and NF-κB signaling that promotes colon cancer progression. Oncogene. 32:3220–3230. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Zhou Z, Lu H, Zhu S, Gomaa A, Chen Z, Yan J, Washington K, El-Rifai W, Dang C and Peng D: Activation of EGFR-DNA-PKcs pathway by IGFBP2 protects esophageal adenocarcinoma cells from acidic bile salts-induced DNA damage. J Exp Clin Cancer Res. 38:132019. View Article : Google Scholar : PubMed/NCBI | |
|
Chen X, Zheng J, Zou Y, Song C, Hu X and Zhang CC: IGF binding protein 2 is a cell-autonomous factor supporting survival and migration of acute leukemia cells. J Hematol Oncol. 6:722013. View Article : Google Scholar : PubMed/NCBI | |
|
Li T, Zhang C, Zhao G, Zhang X, Hao M, Hassan S, Zhang M, Zheng H, Yang D, Liu L, et al: IGFBP2 regulates PD-L1 expression by activating the EGFR-STAT3 signaling pathway in malignant melanoma. Cancer Lett. 477:19–30. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Das SK, Bhutia SK, Azab B, Kegelman TP, Peachy L, Santhekadur PK, Dasgupta S, Dash R, Dent P, Grant S, et al: MDA-9/syntenin and IGFBP-2 promote angiogenesis in human melanoma. Cancer Res. 73:844–854. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Yao X, Wang Y, Duan Y, Zhang Q, Li P, Jin R, Tao Y, Zhang W, Wang X, Jing C and Zhou X: IGFBP2 promotes salivary adenoid cystic carcinoma metastasis by activating the NF-κB/ZEB1 signaling pathway. Cancer Lett. 432:38–46. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
De Craene B and Berx G: Regulatory networks defining EMT during cancer initiation and progression. Nat Rev Cancer. 13:97–110. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Puisieux A, Brabletz T and Caramel J: Oncogenic roles of EMT-inducing transcription factors. Nat Cell Biol. 16:488–494. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Maier HJ, Schmidt-Strassburger U, Huber MA, Wiedemann EM, Beug H and Wirth T: NF-kappaB promotes epithelial-mesenchymal transition, migration and invasion of pancreatic carcinoma cells. Cancer Lett. 295:214–228. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Azar WJ, Azar SH, Higgins S, Hu JF, Hoffman AR, Newgreen DF, Werther GA and Russo VC: IGFBP-2 enhances VEGF gene promoter activity and consequent promotion of angiogenesis by neuroblastoma cells. Endocrinology. 152:3332–3342. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Png KJ, Halberg N, Yoshida M and Tavazoie SF: A microRNA regulon that mediates endothelial recruitment and metastasis by cancer cells. Nature. 481:190–194. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Godard S, Getz G, Delorenzi M, Farmer P, Kobayashi H, Desbaillets I, Nozaki M, Diserens AC, Hamou MF, Dietrich PY, et al: Classification of human astrocytic gliomas on the basis of gene expression: A correlated group of genes with angiogenic activity emerges as a strong predictor of subtypes. Cancer Res. 63:6613–6625. 2003.PubMed/NCBI | |
|
Azar WJ, Zivkovic S, Werther GA and Russo VC: IGFBP-2 nuclear translocation is mediated by a functional NLS sequence and is essential for its pro-tumorigenic actions in cancer cells. Oncogene. 33:578–588. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Maniotis AJ, Folberg R, Hess A, Seftor EA, Gardner LM, Pe'er J, Trent JM, Meltzer PS and Hendrix MJ: Vascular channel formation by human melanoma cells in vivo and in vitro: Vasculogenic mimicry. Am J Pathol. 155:739–752. 1999. View Article : Google Scholar : PubMed/NCBI | |
|
Seftor RE, Seftor EA, Koshikawa N, Meltzer PS, Gardner LM, Bilban M, Stetler-Stevenson WG, Quaranta V and Hendrix MJ: Cooperative interactions of laminin 5 gamma2 chain, matrix metalloproteinase-2, and membrane type-1-matrix/metalloproteinase are required for mimicry of embryonic vasculogenesis by aggressive melanoma. Cancer Res. 61:6322–6327. 2001.PubMed/NCBI | |
|
Park KH, Gad E, Goodell V, Dang Y, Wild T, Higgins D, Fintak P, Childs J, Dela Rosa C and Disis ML: Insulin-like growth factor-binding protein-2 is a target for the immunomodulation of breast cancer. Cancer Res. 68:8400–8409. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Cai J, Chen Q, Cui Y, Dong J, Chen M, Wu P and Jiang C: Immune heterogeneity and clinicopathologic characterization of IGFBP2 in 2447 glioma samples. OncoImmunology. 7:e14265162018. View Article : Google Scholar : PubMed/NCBI | |
|
Li Y, Jiang T, Zhang J, Zhang B, Yang W, You G, Xu K, Wu J, Luo C and Song SW: Elevated serum antibodies against insulin-like growth factor-binding protein-2 allow detecting early-stage cancers: Evidences from glioma and colorectal carcinoma studies. Ann Oncol. 23:2415–2422. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Zhai H, Heppner FL and Tsirka SE: Microglia/macrophages promote glioma progression. Glia. 59:472–485. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Chesik D, De Keyser J and Wilczak N: Involvement of insulin-like growth factor binding protein-2 in activated microglia as assessed in post mortem human brain. Neurosci Lett. 362:14–16. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Elmlinger MW, Deininger MH, Schuett BS, Meyermann R, Duffner F, Grote EH and Ranke MB: In vivo expression of insulin-like growth factor-binding protein-2 in human gliomas increases with the tumor grade. Endocrinology. 142:1652–1658. 2001. View Article : Google Scholar : PubMed/NCBI | |
|
Firth SM and Baxter RC: Cellular actions of the insulin-like growth factor binding proteins. Endocr Rev. 23:824–854. 2002. View Article : Google Scholar : PubMed/NCBI | |
|
Pereira JJ, Meyer T, Docherty SE, Reid HH, Marshall J, Thompson EW, Rossjohn J and Price JT: Bimolecular interaction of insulin-like growth factor (IGF) binding protein-2 with alphavbeta3 negatively modulates IGF-I-mediated migration and tumor growth. Cancer Res. 64:977–984. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Hoeflich A, Nedbal S, Blum WF, Erhard M, Lahm H, Brem G, Kolb HJ, Wanke R and Wolf E: Growth inhibition in giant growth hormone transgenic mice by overexpression of insulin-like growth factor-binding protein-2. Endocrinology. 142:1889–1898. 2001. View Article : Google Scholar : PubMed/NCBI | |
|
Conover CA: Insulin-like growth factor-binding proteins and bone metabolism. Am J Physiol Endocrinol Metab. 294:E10–E14. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Lund J, Søndergaard MT, Conover CA and Overgaard MT: Heparin-binding mechanism of the IGF2/IGF-binding protein 2 complex. J Mol Endocrinol. 52:345–355. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Šunderić M, Đukanović B, Malenković V and Nedić O: Molecular forms of the insulin-like growth factor-binding protein-2 in patients with colorectal cancer. Exp Mol Pathol. 96:48–53. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Miyamoto S, Nakamura M, Yano K, Ishii G, Hasebe T, Endoh Y, Sangai T, Maeda H, Shi-Chuang Z, Chiba T and Ochiai A: Matrix metalloproteinase-7 triggers the matricrine action of insulin-like growth factor-II via proteinase activity on insulin-like growth factor binding protein 2 in the extracellular matrix. Cancer Sci. 98:685–691. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Rorive S, Berton A, D'Haene N, Takacs CN, Debeir O, Decaestecker C and Salmon I: Matrix metalloproteinase-9 interplays with the IGFBP2-IGFII complex to promote cell growth and motility in astrocytomas. Glia. 56:1679–1690. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Shen X, Xi G, Maile LA, Wai C, Rosen CJ and Clemmons DR: Insulin-like growth factor (IGF) binding protein 2 functions coordinately with receptor protein tyrosine phosphatase β and the IGF-I receptor to regulate IGF-I-stimulated signaling. Mol Cell Biol. 32:4116–4130. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Russo VC, Schütt BS, Andaloro E, Ymer SI, Hoeflich A, Ranke MB, Bach LA and Werther GA: Insulin-like growth factor binding protein-2 binding to extracellular matrix plays a critical role in neuroblastoma cell proliferation, migration, and invasion. Endocrinology. 146:4445–4455. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Wang GK, Hu L, Fuller GN and Zhang W: An interaction between insulin-like growth factor-binding protein 2 (IGFBP2) and integrin alpha5 is essential for IGFBP2-induced cell mobility. J Biol Chem. 281:14085–14091. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Schütt BS, Langkamp M, Rauschnabel U, Ranke MB and Elmlinger MW: Integrin-mediated action of insulin-like growth factor binding protein-2 in tumor cells. J Mol Endocrinol. 32:859–868. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Mendes KN, Wang GK, Fuller GN and Zhang W: JNK mediates insulin-like growth factor binding protein 2/integrin alpha5-dependent glioma cell migration. Int J Oncol. 37:143–153. 2010.PubMed/NCBI | |
|
Carnero A and Paramio JM: The PTEN/PI3K/AKT pathway in vivo, cancer mouse models. Front Oncol. 4:2522014. View Article : Google Scholar : PubMed/NCBI | |
|
Levitt RJ, Georgescu MM and Pollak M: PTEN-induction in U251 glioma cells decreases the expression of insulin-like growth factor binding protein-2. Biochem Biophys Res Commun. 336:1056–1061. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Scrideli CA, Carlotti CG Jr, Mata JF, Neder L, Machado HR, Oba-Sinjo SM, Rosemberg S, Marie SK and Tone LG: Prognostic significance of co-overexpression of the EGFR/IGFBP-2/HIF-2A genes in astrocytomas. J Neurooncol. 83:233–239. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Villani RM, Adolphe C, Palmer J, Waters MJ and Wainwright BJ: Patched1 inhibits epidermal progenitor cell expansion and basal cell carcinoma formation by limiting Igfbp2 activity. Cancer Prev Res (Phila). 3:1222–1234. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Foulstone EJ, Zeng L, Perks CM and Holly JM: Insulin-like growth factor binding protein 2 (IGFBP-2) promotes growth and survival of breast epithelial cells: Novel regulation of the estrogen receptor. Endocrinology. 154:1780–1793. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Yuan Q, Cai HQ, Zhong Y, Zhang MJ, Cheng ZJ, Hao JJ, Wang MR and Wan JH: Overexpression of IGFBP2 mRNA predicts poor survival in patients with glioblastoma. Biosci Rep. 39:BSR201900452019. View Article : Google Scholar : PubMed/NCBI | |
|
Han S, Meng L, Han S, Wang Y and Wu A: Plasma IGFBP-2 levels after postoperative combined radiotherapy and chemotherapy predict prognosis in elderly glioblastoma patients. PLoS One. 9:e937912014. View Article : Google Scholar : PubMed/NCBI | |
|
Gállego Pérez-Larraya J, Paris S, Idbaih A, Dehais C, Laigle-Donadey F, Navarro S, Capelle L, Mokhtari K, Marie Y, Sanson M, et al: Diagnostic and prognostic value of preoperative combined GFAP, IGFBP-2, and YKL-40 plasma levels in patients with glioblastoma. Cancer. 120:3972–3980. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
So AI, Levitt RJ, Eigl B, Fazli L, Muramaki M, Leung S, Cheang MC, Nielsen TO, Gleave M and Pollak M: Insulin-like growth factor binding protein-2 is a novel therapeutic target associated with breast cancer. Clin Cancer Res. 14:6944–6954. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Kalledsøe L, Dragsted LO, Hansen L, Kyrø C, Grønbæk H, Tjønneland A and Olsen A: The insulin-like growth factor family and breast cancer prognosis: A prospective cohort study among postmenopausal women in Denmark. Growth Horm IGF Res. 44:33–42. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Sohn J, Do KA, Liu S, Chen H, Mills GB, Hortobagyi GN, Meric-Bernstam F and Gonzalez-Angulo AM: Functional proteomics characterization of residual triple-negative breast cancer after standard neoadjuvant chemotherapy. Ann Oncol. 24:2522–2526. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Probst-Hensch NM, Steiner JH, Schraml P, Varga Z, Zürrer-Härdi U, Storz M, Korol D, Fehr MK, Fink D, Pestalozzi BC, et al: IGFBP2 and IGFBP3 protein expressions in human breast cancer: Association with hormonal factors and obesity. Clin Cancer Res. 16:1025–1032. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Richardsen E, Ukkonen T, Bjørnsen T, Mortensen E, Egevad L and Busch C: Overexpression of IGBFB2 is a marker for malignant transformation in prostate epithelium. Virchows Arch. 442:329–335. 2003. View Article : Google Scholar : PubMed/NCBI | |
|
Mita K, Nakahara M and Usui T: Expression of the insulin-like growth factor system and cancer progression in hormone-treated prostate cancer patients. Int J Urol. 7:321–329. 2000. View Article : Google Scholar : PubMed/NCBI | |
|
Lancaster JM, Sayer RA, Blanchette C, Calingaert B, Konidari I, Gray J, Schildkraut J, Schomberg DW, Marks JR and Berchuck A: High expression of insulin-like growth factor binding protein-2 messenger RNA in epithelial ovarian cancers produces elevated preoperative serum levels. Int J Gynecol Cancer. 16:1529–1535. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Huang YF, Cheng WF, Wu YP, Cheng YM, Hsu KF and Chou CY: Circulating IGF system and treatment outcome in epithelial ovarian cancer. Endocr Relat Cancer. 21:217–229. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Zhang Y, Ying X, Han S, Wang J, Zhou X, Bai E, Zhang J and Zhu Q: Autoantibodies against insulin-like growth factorbinding protein-2 as a serological biomarker in the diagnosis of lung cancer. Int J Oncol. 42:93–100. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Hur H, Yu EJ, Ham IH, Jin HJ and Lee D: Preoperative serum levels of insulin-like growth factor-binding protein 2 predict prognosis of gastric cancer patients. Oncotarget. 8:10994–11003. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Warnecke-Eberz U, Metzger R, Holscher AH, Drebber U and Bollschweiler E: Diagnostic marker signature for esophageal cancer from transcriptome analysis. Tumour Biol. 37:6349–6358. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Myers AL, Lin L, Nancarrow DJ, Wang Z, Ferrer-Torres D, Thomas DG, Orringer MB, Lin J, Reddy RM, Beer DG and Chang AC: IGFBP2 modulates the chemoresistant phenotype in esophageal adenocarcinoma. Oncotarget. 6:25897–25916. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Zhang W, Wang H, Song SW and Fuller GN: Insulin-like growth factor binding protein 2: Gene expression microarrays and the hypothesis-generation paradigm. Brain Pathol. 12:87–94. 2002. View Article : Google Scholar : PubMed/NCBI | |
|
Juncker-Jensen A, Lykkesfeldt AE, Worm J, Ralfkiaer U, Espelund U and Jepsen JS: Insulin-like growth factor binding protein 2 is a marker for antiestrogen resistant human breast cancer cell lines but is not a major growth regulator. Growth Horm IGF Res. 16:224–239. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Neuhouser ML, Platz EA, Till C, Tangen CM, Goodman PJ, Kristal A, Parnes HL, Tao Y, Figg WD, Lucia MS, et al: Insulin-like growth factors and insulin-like growth factor-binding proteins and prostate cancer risk: Results from the prostate cancer prevention trial. Cancer Prev Res (Phila). 6:91–99. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Tennant MK, Thrasher JB, Twomey PA, Birnbaum RS and Plymate SR: Insulin-like growth factor-binding protein-2 and −3 expression in benign human prostate epithelium, prostate intraepithelial neoplasia, and adenocarcinoma of the prostate. J Clin Endocrinol Metab. 81:411–420. 1996. View Article : Google Scholar : PubMed/NCBI | |
|
Bubendorf L, Kolmer M, Kononen J, Koivisto P, Mousses S, Chen Y, Mahlamäki E, Schraml P, Moch H, Willi N, et al: Hormone therapy failure in human prostate cancer: Analysis by complementary DNA and tissue microarrays. J Natl Cancer Inst. 91:1758–1764. 1999. View Article : Google Scholar : PubMed/NCBI | |
|
Karasik A, Menczer J, Pariente C and Kanety H: Insulin-like growth factor-I (IGF-I) and IGF-binding protein-2 are increased in cyst fluids of epithelial ovarian cancer. J Clin Endocrinol Metab. 78:271–276. 1994. View Article : Google Scholar : PubMed/NCBI | |
|
Yee D, Morales FR, Hamilton TC and Von Hoff DD: Expression of insulin-like growth factor I, its binding proteins, and its receptor in ovarian cancer. Cancer Res. 51:5107–5112. 1991.PubMed/NCBI | |
|
Hu Q, Huang L, Kuang X, Zhang H, Ling G, Chen X, Li K, Deng Z and Zhou J: Is insulin-like growth factor binding protein 2 associated with metastasis in lung cancer? Clin Exp Metastasis. 31:535–541. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Wang J, Hu ZG, Li D, Xu JX and Zeng ZG: Gene expression and prognosis of insulin-like growth factor-binding protein family members in non-small cell lung cancer. Oncol Rep. 42:1981–1995. 2019.PubMed/NCBI | |
|
Yazawa T, Sato H, Shimoyamada H, Okudela K, Woo T, Tajiri M, Ogura T, Ogawa N, Suzuki T, Mitsui H, et al: Neuroendocrine cancer-specific up-regulating mechanism of insulin-like growth factor binding protein-2 in small cell lung cancer. Am J Pathol. 175:976–987. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Pickard A and McCance DJ: IGF-Binding Protein 2 - Oncogene or tumor suppressor? Front Endocrinol (Lausanne). 6:252015. View Article : Google Scholar : PubMed/NCBI | |
|
Chen R, Brentnall TA, Pan S, Cooke K, Moyes KW, Lane Z, Crispin DA, Goodlett DR, Aebersold R and Bronner MP: Quantitative proteomics analysis reveals that proteins differentially expressed in chronic pancreatitis are also frequently involved in pancreatic cancer. Mol Cell Proteomics. 6:1331–1342. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Yi HK, Hwang PH, Yang DH, Kang CW and Lee DY: Expression of the insulin-like growth factors (IGFs) and the IGF-binding proteins (IGFBPs) in human gastric cancer cells. Eur J Cancer. 37:2257–2263. 2001. View Article : Google Scholar : PubMed/NCBI |
